1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Equipment & Services
CapsoVision, Inc.

CapsoVision, Inc.

CV
CapsoVision, Inc.US flagNASDAQ Global Select
- -
USD
- -
- -
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
0.25
- -
0.3
Basic EPS, GAAP
-0.29
-0.43
- -
-0.57
Free Cash Flow per Basic Share
-0.3
-0.44
- -
-0.52
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-2.86
-2.81
- -
-3.5
Tangible Book Value per Share
-4.52
-4.51
- -
0.3
Basic Weighted Avg Shares
39
46
- -
44
Sales/Revenue/Turnover
10
12
14
14
Operating Margin (%)
-116.34
-169.42
-188.25
-188.25
Depreciation Expense
- -
1
1
1
Net Income, GAAP
-11
-20
-25
-25
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-115.91
-169.26
-186.77
-186.77
Working Capital
18
13
12
12
LT Debt
1
1
- -
- -
Total Equity
-110
-130
13
13
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
47
47
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
8
24
17
Cash, Cash Equivalents & STI
1
18
10
Accounts Receivable, Net
2
2
2
Inventories
3
3
3
Total Current Liabilities
4
5
4
Payables & Accruals
2
3
3
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-110.24%
Free Cash Flow
- -
- -
13.39%
Net Income, GAAP
- -
- -
27.22%
Sales/Revenue/Turnover
- -
- -
15.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10
2024
2
3
3
3
12
2025
3
3
4
4
14

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.29
2024
-0.1
-0.13
-0.14
- -
-0.43
2025
-0.13
-0.1
-0.17
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Kang-Huai Wang
Full Time Employees
90
Sector
Healthcare
Industry
Medical - Equipment & Services
Address
Cox Avenue Saratoga CA United States of America 95070
IPO Date
Sep 3, 2001
CIK
0001378325
Website
capsovision.com
Similar Companies
Cotiviti Holdings, Inc. (COTV)
Hoshi Iryo-Sanki Co., Ltd. (7634.T)
Spectranetics Corp. (The) (SPNC)
Hi-Clearance Inc. (1788.TWO)
Revenio Group Oyj (0KFH.L)
Nexus AG (0FGL.L)
Business
CapsoVision, Inc. (NASDAQ: CV) develops and commercializes advanced imaging and artificial intelligence-enabled capsule endoscopy solutions for the detection and diagnosis of gastrointestinal diseases. The company offers CapsoCam Plus, a wire-free, single-use capsule endoscope providing 360-degree panoramic visualization of the small bowel mucosa in adults and children aged two years and above; CapsoCam Colon for non-invasive colon imaging, polyp detection, and measurement; and CapsoColon 3D in development for large intestine applications. Complementary products and services include CapsoCloud, a cloud-based software-as-a-service platform for remote video access, download, and AI-assisted analysis; CapsoAccess, a capsule data retrieval system; CapsoView software for direct video review; CapsoRetrieve retrieval kit using magnetic technology; and capsule video reading services. CapsoVision serves gastroenterologists, medical practices, clinics, and hospitals, selling directly in the United States and through exclusive distributors internationally, with key markets in France, Germany, and Canada. The company operates globally from its headquarters in Saratoga, California, where it was incorporated in 2005, and established a direct sales team in Germany in 2023 to expand its European presence. Recent developments include the completion of an initial public offering in July 2025, raising net proceeds of $23.4 million; submission of an FDA Breakthrough Device Designation application in November 2025 for a capsule targeting early-stage pancreatic cancer detection; entry into a development agreement with Canon Inc. in 2025 for higher-resolution CMOS image sensors; appointment of David Garcia as Senior Vice President of Finance in November 2025; advancement of AI-assisted reading updates for CapsoCam Plus with planned FDA submission by end-2025; and commencement of clinical enrollment for a next-generation colon capsule.